Achieve Life Sciences Inc ACHV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
-
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
-
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
-
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
-
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
-
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
-
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
-
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Trading Information
- Previous Close Price
- $6.54
- Day Range
- $6.45–6.94
- 52-Week Range
- $2.62–8.64
- Bid/Ask
- $6.00 / $7.50
- Shares Outstanding
- 103.10M
- Market Cap
- $714.50M
- Volume/Avg
- 1,195 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
Valuation
|
Metric
|
ACHV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ACHV
Financial Strength
|
Metric
|
ACHV
|
|---|---|
Quick Ratio | 0.95 |
Current Ratio | 0.95 |
Interest Coverage | −116.50 |
Quick Ratio
ACHV
Profitability
|
Metric
|
ACHV
|
|---|---|
Return on Assets (Normalized) | −138.31% |
Return on Equity (Normalized) | −560.83% |
Return on Invested Capital (Normalized) | −335.88% |
Return on Assets
ACHV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$>LLphS | LOCK|yjPsY | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|RD@YNK | LOCK|T>xJ | $84B | |||
| Moderna Inc
MRNA
| LOCK|$hQgXs | LOCK|#T | $83B | |||
| argenx SE ADR
ARGX
| LOCK|TBlv#xD | LOCK|sHH | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#>C&@%% | LOCK|Cll | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?wWKnQ | LOCK|R%<R | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|R!Qk^W## | LOCK|!#@D | $29B | |||
| Incyte Corp
INCY
| LOCK|v?&HSlt | LOCK|Dcc | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Z&L$HB | LOCK|Rl | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|#gv$Msl | LOCK|y^% | $14B |
United States